Member Login
Market Reports
 |
|
The allergy drug market has intense competitions. The market shares from the top 20 companies account for about 88.44% of the Chinese hospital allergy drug market in 2007, which is similar to the situation in 2006. However, many generic products have recently been introduced in the market and have intensified the market competition.
This report has systemically analyzed the Chinese allergy drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.
This China Allergy Drug Market Report has been a Must-have reference for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties. *** This is a partial list of companies, for a full listing request it ***
* Single License allows for report sharing within one company location.
Statistic data indicate that the Chinese incidence of allergy diseases is as high as 37.3%. The incidences of allergy in the eastern coastal regions are higher than that in the inner land. The incidences of allergy in industrialized regions are higher than that in the rural areas. Under the government pricing control policies, the market growth of the allergy drugs has slowed down significantly in 2007. The sales of allergy drugs are about $557 million with only 2.63% growth in 2007.
Top 20 Pharmaceutical Companies in China's Anti-Allergic Drug Market (at least with >0.84% of the total market shares)
Chapter I: Overview of Allergy Drugs
Section 1: Overview of Allergy Drugs
Allergic Rhinitis (AR)
Allergic Asthma (AA)
Allergic Purpura (AP)
Anti-allergy Drugs
1. The 1st generation antihistamine drugs
2. The 2nd generation antihistamine drugs
3. The 3rd generation antihistamine drugs
Section 2: R&D of Allergy drugs
Chapter II: The Chinese Market of Allergy Drugs
Section 1: Market size of Allergy Drugs
Section 2: Market Shares of Top Allergy Drugs
Section 3: Market Shares of the Top 20 Pharmaceutical Companies in the Chinese Allergy Drug Market
Section 4: Growth Analysis of Top Allergy Drugs
Section 5: New Drug Approvals and Patent Applications of Allergy Drugs
5.1 Newly Approved Allergy Drugs in 2007 in China
5.2 Patent Applications for Allergy Drugs in China
Chapter III: Key Allergy Drugs in the Chinese Market
Section 1: Market Shares, Market Sizes and Manufacturers of Loratadine
Section 2: Market Shares, Market Sizes and Manufacturers of Cetirizine
Section 3: Market Shares, Market Sizes and Manufacturers of Desloratadine
Section 4: Market Shares, Market Sizes and Manufacturers of Mizolastine
Section 5: Market Shares, Market Sizes and Manufacturers Levocetirizine
Section 6: Market Shares, Market Sizes and Manufacturers of Ebastine
Section 7: Market Shares, Market Sizes and Manufacturers of Epinastine
Section 8: Market Shares, Market Sizes and Manufacturers of Fexofenadine
Section 9: Global Sales of Allergy Drugs
Chapter IV: Pricing Control on Allergy Drugs & Allergy Drugs on the National Basic Healthcare Insurance List
Section 1: Price Control on Certain Drugs
Section 2: Allergy Drugs on the National Basic Healthcare Insurance List-04
Chapter V: Brand Names, Chemical Names and Manufacturers of Allergy Drugs in China
Table 1: Market Shares of Top Allergy Drugs in China 2005-2007
Table 2: Market Shares of the Top 20 Pharmaceutical Companies in the Chinese Allergy Market 2006-2007
Table 3: Growth Rates of the Top 15 Allergy Drugs 2006-2007
Table 4: New Approvals of Major Allergy Drugs in 2007
Table 5: New Patents on Allergy Drugs in 2007
Table 6: Manufacturers, Formula, Brands and Market Shares of Loratadine 2006-2007
Table 7: Sales of Loratadine by Manufacturers 2006-2007
Table 8: Manufacturers, Formula, Brands and Market Shares of Cetirizine 2006-2007
Table 9: Sales of Cetirizine by Manufacturers 2006-2007
Table 10: Manufacturers, Formula, Brands and Market Shares of Desloratadine 2006-2007
Table 11: Sales of Desloratadine by Manufacturers 2006-2007
Table 12: Manufacturers, Formula, Brands and Market Shares of Mizolastine 2006-2007
Table 13: Sales of Mizolastine by Manufacturers 2006-2007
Table 14: Manufacturers, Formula, Brands and Market Shares of Levocetirizine 2006-2007
Table 15: Sales of Levocetirizine by Manufacturers 2006-2007
Table 16: Manufacturers, Formula, Brands and Market Shares of Ebastine 2006-2007
Table 17: Sales of Ebastine by Manufacturers 2006-2007
Table 18: Manufacturers, Formula, Brands and Market Shares of Epinastine 2006-2007
Table 19: Sales of Epinastine by Manufacturers 2006-2007
Table 20: Manufacturers, Formula, Brands and Market Shares of Fexofenadine 2006-2007
Table 21: Sales of Fexofenadine by Manufacturers 2006-2007
Table 22: Sales of Allergy Drugs in the World 2007
Table 23: Ranking of the Prescription Drugs by Prescription Volumes
Table 24: New Maximum Retail Prices of Patented and Innovative Allergy Drugs 2007
Table 25: New Maximum Retail Prices of GMP Allergy Drugs 2007
Table 26: Allergy Drugs on the National Basic Healthcare Insurance Lists 2004
Table 27: Brand Names, Chemical Names and Manufacturers of Allergy Drugs in China
Figure 1: Sales Trends of Allergy Drugs 2005-2007
Top 20 Pharmaceutical Companies in China's Anti-Allergic Drug Market (at least with >0.84% of the total market shares)
•Chongqing Huabang
•India Ranbaxy Labs
•Shenzhen Xinlitai
•Zhejiang Hangzhou Aoyi Baoling
•Beijing Shuanglu
•Chengdu Minyi
•Chongqing Kailin
•Guangdong Zhuhai Lianbang
•Hainan Puli
•Henan Sanmenxia Sainuowei
•Hubei Yidu Dongyang
•Jiangsu Changzhou No 4 Pharma
•Jiangsu Lianhuan
•Nanjing Yihua
•Schering-Plough China
•Shandong Lunan
•Shenzhen Haibin
•Eisai
•UCB
•Xian-Janssen
Chongqing Huabang
India Ranbaxy Labs
Shenzhen Xinlitai
Zhejiang Hangzhou Aoyi Baoling
Beijing Shuanglu
Chengdu Minyi
Chongqing Kailin
Guangdong Zhuhai Lianbang
Hainan Puli
Henan Sanmenxia Sainuowei
Hubei Yidu Dongyang
Jiangsu Changzhou No 4 Pharma
Jiangsu Lianhuan
Nanjing Yihua
Schering-Plough China
Shandong Lunan
Shenzhen Haibin
Eisai
UCB
Xian-Janssen
+ MORE
** Corporate License allows for report sharing within all company locations.
This report is listed in the following markets:
Drug Delivery and Respiratory